Pharmatory set to expand Oulu’s pharmaceutical manufacturing capabilities in 2028
At a time when much of the discussion around European manufacturing focuses on industrial decline and the challenges of maintaining production capacity, one Oulu-based manufacturer, Pharmatory, is taking a significant step forward.
Founded in 2001, Pharmatory develops manufacturing processes and produces active pharmaceutical ingredients (APIs) — the chemical substances that form the basis of medicines. Working with pharmaceutical and biotechnology companies around the world, the company has built its expertise on solving complex chemistry challenges and turning laboratory processes into reliable manufacturing operations. Now, Pharmatory is preparing for its next chapter, with a new facility dedicated to highly potent active pharmaceutical ingredients (HPAPIs) scheduled to begin operations in 2028.
The expansion is being supported by investment from Finnish private equity investor MB Funds, helping to accelerate the development of new manufacturing infrastructure and Pharmatory’s entry into the growing HPAPI market.
A different level of containment
HPAPIs are used in medicines such as cancer treatments and other targeted therapies. While the chemistry involved may be familiar to experienced pharmaceutical manufacturers, working with these compounds brings an entirely different set of challenges. Because they can have biological effects at extremely low concentrations, their manufacture requires specialised facilities, equipment and working practices. Containment systems are essential to protect employees from exposure and prevent cross-contamination between products.
“Manufacturing highly potent compounds requires us to look at the entire process, from material handling and synthesis to cleaning and waste management. It’s not simply a question of producing the compound itself, but making sure every stage can be carried out safely and reliably,” says Pharmatory’s Managing Director, Dr Jaana Karjalainen.
Preparing for production
As preparations continue for the opening of its new facility, Pharmatory recently welcomed containment specialists from SafeBridge Europe and containment technology company ILC Dover to its Oulu site.
Together, the teams tested newly installed production isolators. These enclosed systems are designed to prevent exposure to highly potent pharmaceutical ingredients. More than 180 samples were collected to verify the equipment’s containment performance and ensure it meets safety requirements ahead of production.
As the project reached its final testing phase, the visiting team reflected positively on the collaboration:
“Simon Adcock & Neil Cocker of ILC Dover (an Ingersoll Rand Company) recently visited Pharmatory to complete the final stages of a High Containment project — testing the three recently installed Flexible Containment Isolators specifically designed to upgrade the existing equipment and processes. Having started the project with an initial site visit in November 2024, Simon & Neil have developed a close working relationship with the Pharmatory Team, exceeding the traditional customer/supplier relationship to one bordering on friendship, a key factor to the success of the project. While the primary focus has always been delivery of the Containment systems, each visit to Oulu has been memorable for the kind hospitality shown by our hosts & the welcoming locals with incredible local cuisine—sampling reindeer cooked many different ways has been a definite highlight! We are very much looking forward to the next stage of development at Pharmatory and to return visits, hopefully in the warmer summer months!”
A new milestone for Pharmatory
“For Pharmatory, this investment represents an important step in our future growth. It will allow us to support customers whose drug candidates require specialised manufacturing capabilities, while building on the chemistry expertise we have developed over the past 25 years.” says Dr. Jaana Karjalainen. “We are proud to be taking this next step in Oulu, strengthening local pharmaceutical expertise and contributing to the region’s life science ecosystem.”
The new facility will broaden Pharmatory’s capabilities and create opportunities to work on a wider range of pharmaceutical projects. It also marks another step forward for Oulu’s growing life science sector. With operations scheduled to begin in 2028, Pharmatory is looking ahead to supporting the development of tomorrow’s medicines from its home in Laanila, Oulu.
Source (text and image): Pharmatory


